Randomized Study of Quercetin Supplementation to Improve Lung Health in Adults with Idiopathic and Other Fibrotic Interstitial Lung Diseases

What this Trial Is About

Fibrotic interstitial lung diseases F-ILDs, including idiopathic pulmonary fibrosis IPF and other fibrotic forms, are chronic lung conditions marked by excessive scarring that leads to worsening lung function, respiratory failure, and high mortality despite current antifibrotic treatments. The causes are linked to aging, genetics, environmental factors, and cellular aging. This trial aims to study the effects of quercetin supplementation on biological markers and lung function in patients with IPF and F-ILDs to explore new treatment approaches. Participants will be randomly assigned to either receive quercetin dietary supplements 500 mg daily for two 12-week cycles separated by an 8-week break, in addition to their usual antifibrotic or immunomodulatory treatment, or to continue with their standard care alone. The study compares these two groups to evaluate changes in several lung-related health markers and biological proteins related to cellular aging and inflammation. During the 32-week study period, patients will undergo assessments including blood tests for telomere length and inflammatory proteins, lung function tests like spirometry and oscillometry, fractional exhaled nitric oxide measurement, and quality of life questionnaires. These evaluations will occur at the start and end of the study to measure changes and monitor safety. The goal is to understand how quercetin might impact lung fibrosis and overall patient health.

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.